Korsana Biosciences, Inc. (KRSA) stock
KRSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30493% above fair value
$32.50−0.18 (-0.55%)
Close on Nov 17, 2026Market cap $152.14MP/E –Yield –
Korsana Biosciences price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Korsana Biosciences's price to sales ratio was 71.3× on Nov 11, 2026, against 14.3× a year earlier. Over the last 5 years it ranged from 5.7× to 445.0×, with a median of 113.0×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 71.3× | +59.8 |
| 2025 | Dec 31, 2025 | 11.5× | −282.5 |
| 2024 | Dec 31, 2024 | 294.1× | +134.9 |
| 2023 | Jul 31, 2023 | 159.1× | +30.2 |
| 2022 | Dec 30, 2022 | 128.9× | −18.3 |
| 2021 | Dec 31, 2021 | 147.2× | −52.4 |
| 2020 | Dec 31, 2020 | 199.6× | – |
See a number that looks wrong?